We evaluated the selective GR modulator relacorilant plus nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had received at least 2 prior therapy lines. The gene discussed is NR3C1; the disease is pancreatic ductal adenocarcinoma.